Comparative Pharmacology
Head-to-head clinical analysis: ELIXOPHYLLIN SR versus VOSPIRE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELIXOPHYLLIN SR versus VOSPIRE ER.
ELIXOPHYLLIN SR vs VOSPIRE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular cAMP, and antagonizing adenosine receptors. It also has anti-inflammatory effects by reducing eosinophil infiltration and cytokine release.
Vospire ER (albuterol sulfate) is a beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via activation of adenylyl cyclase, leading to bronchodilation.
300-600 mg orally every 12 hours; extended-release tablets. Adjust based on serum theophylline concentrations (target 5-15 mcg/mL).
Oral: 30-60 mg once daily in the morning, with or without food. Maximum dose: 60 mg/day.
None Documented
None Documented
Terminal elimination half-life: 7-9 hours in adults (nonsmokers). In smokers, hepatic clearance is increased, reducing half-life to 4-5 hours. In patients with hepatic cirrhosis, half-life may extend to 24 hours. In neonates, half-life is prolonged (20-30 hours).
Terminal elimination half-life of vospire ER is approximately 12-15 hours. This prolonged half-life supports once-daily dosing and provides sustained bronchodilation over the dosing interval.
Renal: approximately 90% of the dose is eliminated via hepatic metabolism (N-demethylation and hydroxylation), with about 10% excreted unchanged in urine. The primary metabolites are 1-methylxanthine, 1,3-dimethyluric acid, and 3-methylxanthine. Fecal excretion is negligible (<1%).
Primarily renal (approximately 75% as unchanged drug and metabolites) and biliary/fecal (approximately 25%).
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator